Metabolic
0 drugs are in development for Familial Hypercholesterolemia.
- Companies
- 0
- Clinical trials
- 8
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Familial Hypercholesterolemia pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
About this indication
Familial Hypercholesterolemia context
Metabolic·MeSH: Hyperlipoproteinemia Type II (D006938)
Also known as: Density Lipoproteinemia, Hyper-Low, Density Lipoproteinemias, Hyper-Low, Essential Hypercholesterolemia, Essential Hypercholesterolemias, Familial Hypercholesterolemias, Familial Hypercholesterolemic Xanthomatoses, Familial Hypercholesterolemic Xanthomatosis, Hyper beta Lipoproteinemia, Hyper-beta-Lipoproteinemias, Hyperbetalipoproteinemia, Hyperbetalipoproteinemias, Hyperlipoproteinemia Type 2s, Hyperlipoproteinemia Type II, Hyperlipoproteinemia Type IIs, Hyperlipoproteinemias, Type II, Type 2, Hyperlipoproteinemia, Type II Hyperlipoproteinemia